Skip to main navigation Skip to search Skip to main content

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.

  • for the CC-92480-MM-001 Study Investigators
  • Dana-Farber Cancer Institute
  • University of Toronto
  • University College London Hospitals NHS Foundation Trust
  • Hospital Clínico Universitario de Salamanca
  • University of Copenhagen
  • Oxford University Hospitals NHS Foundation Trust
  • Complutense University
  • University of Melbourne
  • University of Texas MD Anderson Cancer Center
  • Hospital Universitario La Fe
  • Emory University
  • City of Hope National Med Center
  • The Institute of Cancer Research
  • Royal Marsden NHS Foundation Trust
  • Generalitat de Catalunya
  • Sarah Cannon Research Institute
  • University of Navarra
  • Hospital San Pedro de Alcántara
  • Bristol-Myers Squibb
  • University of Calgary

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science